Long-term survival in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL) who achieved minimal residual disease (MRD) response following anti-CD19 BiTE® blinatumomab

This article has no abstract
Epistemonikos ID: 1417e8a64ac9ab0bcecec879592a56f21d086db8
First added on: Feb 06, 2025